Dr. Xie is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
200 1st Street SW
Rochester, MN 55905
Education & Training
Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 2017 - 2020
Yale-New Haven Medical CenterResidency, Internal Medicine, 2014 - 2017
Cleveland Clinic Lerner College of MedicineClass of 2014, MD
Princeton UniversityPhD, Organic Chemistry, 2004 - 2009- Fudan UniversityBS, Chemistry, 2000 - 2004
Certifications & Licensure
FL State Medical License 2020 - 2026
MN State Medical License 2017 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 38 citationsA phase I/Ib study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancer.Richard D Kim, Bence P Kovari, Maria Martinez, Hao Xie, Ibrahim H Sahin
European Journal of Cancer. 2022-07-01 - 57 citationsNeoadjuvant vs. adjuvant chemotherapy for cholangiocarcinoma: A propensity score matched analysis.Siddhartha Yadav, Hao Xie, Irbaz Bin-Riaz, Prabin Sharma, Urshila Durani
European Journal of Surgical Oncology. 2019-08-01 - 9 citationsCopy Number Alterations as Novel Biomarkers and Therapeutic Targets in Colorectal Cancer.Elaine S Tan, Todd C Knepper, Xuefeng Wang, Jennifer B Permuth, Liang Wang
Cancers. 2022-04-29
Lectures
- Phase II trial of trifluridine/tipiracil and irinotecan for the treatment of advanced refractory biliary tract cancer.ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/24/2020
- Patient-derived organoid (PDO), a new personalized therapy selection tool for prompt clinical decision making in metastatic gastrointestinal (mGI) cancer patients.2019 ASCO Annual Meeting - 6/1/2019
- Methylated DNA markers (MDMs) in primary (pCRC) and metastatic colorectal cancers (mCRC).2019 ASCO Annual Meeting - 6/1/2019
Press Mentions
- Liquid Biopsies May Ease Enrollment in Clinical TrialsNovember 6th, 2020
Study Finds DNA Markers May Be Valuable in Early Detection of Colorectal CancerMay 31st, 2019
Colorectal Cancer: Younger Patients Fare WorseJune 30th, 2023
Other Languages
- Chinese (Mandarin)
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
